CD274 and non-small cell lung carcinoma: The most successful immune checkpoint blockade (ICB) therapy is anti-PD-1/PD-L1, which has been shown to confer therapeutic advantages for a variety of cancers, such as non-small cell lung carcinoma (NSCLC), malignant melanoma, kidney cancer, and liver cancer (3–8).